Blair William & Co. IL Has $16.79 Million Holdings in West Pharmaceutical Services, Inc. $WST

Blair William & Co. IL decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 10.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,999 shares of the medical instruments supplier’s stock after selling 7,737 shares during the quarter. Blair William & Co. IL owned 0.09% of West Pharmaceutical Services worth $16,789,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of West Pharmaceutical Services by 193.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 95 shares in the last quarter. SJS Investment Consulting Inc. boosted its position in shares of West Pharmaceutical Services by 1,842.9% during the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 129 shares in the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in West Pharmaceutical Services in the third quarter valued at approximately $47,000. Finally, MUFG Securities EMEA plc bought a new position in West Pharmaceutical Services in the second quarter valued at approximately $47,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $245.92 on Monday. The stock has a market capitalization of $17.71 billion, a PE ratio of 36.22, a PEG ratio of 2.61 and a beta of 1.17. The business’s 50 day simple moving average is $253.72 and its 200 day simple moving average is $262.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.02 and a quick ratio of 2.34. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $322.34.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The firm had revenue of $805.00 million during the quarter, compared to analyst estimates of $795.70 million. During the same quarter last year, the business earned $1.82 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. As a group, research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services announced that its Board of Directors has authorized a share buyback program on Tuesday, February 17th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical instruments supplier to purchase up to 5.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 12.96%.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong‑Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Jefferies Financial Group reiterated a “buy” rating and issued a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Finally, UBS Group reaffirmed a “buy” rating and issued a $340.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $314.56.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.